Anabolic Androgenic Steroid Use & IPED Use Disorders

Course Overview

The clinical presentation of anabolic androgenic steroid use and broader image and performance enhancing drug (IPED) use is often missed because many clinicians still picture a narrow athletic stereotype instead of the population that actually presents in practice. Most adults using these agents are not elite competitors. They are recreational physique-focused men, aging men pursuing vitality or performance, women using androgens or related agents for body composition change, or advanced users layering multiple compounds into mixed exposure states that do not behave like simple one-drug syndromes. Reviews of this population consistently describe delayed disclosure, distrust of traditional healthcare settings, and a high burden of cardiovascular, reproductive, hematologic, psychiatric, and multi-organ complications. [1-6]

This course focuses on how these patients actually enter care, what presentation patterns should raise suspicion, and how clinicians should respond once exposure is on the differential. The emphasis is on psychiatric and neurobehavioral presentation, cardiometabolic and vascular consequences, endocrine and reproductive disruption, renal and hepatic injury, dermatologic and hematologic findings, polypharmacy, disclosure barriers, and ethical clinical positioning. The aim is to understand how exposure changes interpretation, alters risk, and demands a more structured, medically serious diagnostic posture. [1-10]

Learning Objectives

After completing this course, clinicians should be able to:

➀ Recognize the major ways patients using anabolic-androgenic steroids and IPEDs enter clinical care.

➁ Identify common psychiatric, cardiometabolic, endocrine, reproductive, hepatic, renal, dermatologic, and hematologic presentation patterns.

➂ Recognize how polypharmacy complicates symptom attribution and increases risk.

➃ Detect red flags that should prompt direct but nonjudgmental inquiry into AAS or IPED exposure.

➄ Describe common dependence, withdrawal, and use disorder patterns associated with anabolic agents.

➅ Explain why disclosure is frequently delayed and how clinician behavior influences disclosure quality.

➆ Apply a harm-reduction model that supports ethical, evidence-based, and medically rigorous care.

Video Lesson Takeaways

◉ The clinical presentation of AAS and broader iPED use is common in everyday clinical practice and should not be treated as a niche problem limited to elite athletics.

◉ Patients often enter care through the first consequence that became intolerable, such as panic, infertility, erectile dysfunction, resistant hypertension, abnormal liver tests, erythrocytosis, or post-cycle collapse, rather than through voluntary full disclosure.

◉ Psychiatric instability, cardiometabolic injury, endocrine suppression, reproductive dysfunction, renal and hepatic abnormalities, and dermatologic changes should be interpreted as potentially connected parts of one exposure-driven syndrome rather than as isolated findings.

◉ Polypharmacy is common, and clinicians should assume mixed exposure states until history proves otherwise rather than trying to force the case into a single-agent explanation.

◉ Red-flag findings such as very low HDL, elevated hematocrit, disproportionate hypertension, infertility, severe acne, rapid body-composition change, and post-cycle depression should prompt direct, nonjudgmental questioning about AAS and iPED exposure.

◉ Harm reduction is not permissiveness. In this population, it is often the most medically realistic starting point for reducing risk, improving disclosure, and keeping the patient connected to structured care.

◉ The clinician’s first responsibility is not to secure perfect disclosure. It is to recognize the pattern early enough to prevent the next avoidable consequence.

➀ Opening Frame (Positioning & Ethos)

This course should be approached through a harm-reduction lens from the start. That does not mean minimizing risk or endorsing unsafe use. It means recognizing that actively using patients still deserve serious medical care and that a purely exclusionary stance often pushes them further into self-management, gym-based advice networks, and online pharmacology communities that may be highly influential but medically unreliable. Reviews of AAS users repeatedly identify fear of stigma and lack of confidence in physician knowledge as major barriers to care. [1,2,9,10]

That framing changes the purpose of the first encounter. The first visit is rarely the moment where every compound, dose, and recovery attempt is disclosed perfectly. More often, it is the moment where the clinician begins to recognize the syndrome, identifies immediate risk, and makes future disclosure more medically possible. If the physician waits for a complete history before taking the case seriously, the diagnosis will often be late, the patient may disengage, and the opportunity to reduce harm may narrow quickly.

➁ Patient Archetypes (Who Presents)

The patient population is broader than many clinicians expect. Recreational physique-focused individuals remain common, but they are not the only group. Aging men seeking vitality and performance represent another major population, often entering care after self-directed testosterone use or after drifting from “replacement” language into enhancement-oriented behavior. Women using androgens or iPEDs for body composition or performance goals form a smaller but clinically important subgroup, and they may present later because the social cost of disclosure and the fear of visible irreversible change can be even greater. [1-6]

There is also a clinically distinct subgroup of advanced users whose exposure resembles informal endocrine engineering more than isolated steroid use. Recognizing this archetype prevents underestimating risk and diagnostic complexity.

➂ Modes of Presentation (Entry Points into Care)

Patients do not all enter care through the same doorway. Some are symptom-driven and present with anxiety, panic attacks, depression, insomnia, libido loss, erectile dysfunction, fatigue, or cognitive complaints. Others are complication-driven and come in because hypertension, severe dyslipidemia, elevated liver enzymes, elevated hematocrit, infertility, or gynecomastia has finally forced the issue into view. A smaller but clinically important group presents in crisis with acute coronary syndrome, arrhythmia, acute kidney injury, or major psychiatric instability. Another subgroup arrives after a post-cycle crash, during fertility workup, or while seeking supervised discontinuation or harm-reduction guidance. [1-4]

The first patient concern should therefore be treated as an entry point. A patient presenting for infertility may also have severe dyslipidemia, suppressed gonadotropins, and escalating psychiatric distress that were never previously addressed. A patient presenting for panic symptoms may be describing withdrawal physiology rather than an anxiety disorder. The diagnostic task is to identify the larger exposure pattern that made this the first consequence that became intolerable.

➃ Clinical Presentation Domains

Psychiatric and neurobehavioral symptoms are among the most common and most disruptive presentation domains. Anxiety disorders, panic symptoms, major depressive episodes, insomnia, irritability, aggression, and muscle dysmorphia are all well represented in the literature. Timing is especially important. Panic and depression often intensify during withdrawal or after discontinuation, when low endogenous testosterone, sleep disturbance, sexual dysfunction, and loss of physique-based reinforcement converge into a highly unstable state. Muscle dysmorphia and related body image pathology also matter because continued use may be driven less by pleasure than by an inability to tolerate perceived loss of size, strength, control, or identity. [1,3,7-10]

Cardiometabolic and vascular harm deserves disproportionate attention because it is both common and potentially catastrophic. Hypertension, atherogenic lipid changes, accelerated atherosclerosis, left ventricular hypertrophy, cardiomyopathy, and arrhythmia are all relevant concerns. One of the most dangerous assumptions in this field is that a lean, muscular appearance implies low risk. Some of the highest-risk cardiometabolic patients in androgen medicine look externally fit until the workup proves otherwise. [1,3,11-13]

Endocrine and reproductive presentation often becomes the first reason patients seek legitimate care. In men, common patterns include HPG-axis suppression, low endogenous testosterone after discontinuation, erectile dysfunction, loss of libido, infertility, oligospermia or azoospermia, and testicular atrophy. In women, presentation may include virilization, menstrual irregularities, acne, androgenic hair loss, hirsutism, libido shifts, voice deepening, and broader endocrine disruption. These reproductive and hormonal consequences are often more powerful motivators for care-seeking than cosmetic or performance changes. [1,2,14-16]

Renal and hepatic presentation may be more objective and therefore easier to miss if the clinician is thinking too narrowly about hormones. Acute kidney injury, chronic kidney disease progression, elevated creatinine, elevated AST and ALT, and cholestatic injury with oral agents all belong in the diagnostic frame. Dermatologic and physical clues such as severe truncal acne, androgenic alopecia, gynecomastia, and rapid body-composition shifts can also function as visible markers of broader androgen burden. [1,17-19]

Hematologic presentation deserves special emphasis. Androgen-induced erythrocytosis is a common, clinically significant, and under-monitored complication of AAS use. Elevated hematocrit and hemoglobin increase blood viscosity and interact with hypertension, thrombotic risk, sleep apnea, and structural heart disease. This is one of the clearest examples of patients feeling subjectively better while objective risk is rising. [1,20,21]

➄ IPED Polypharmacy Considerations

Modern presentations are frequently mixed and synergistic rather than attributable to a single compound. Growth hormone, insulin, thyroid hormones, clenbuterol and other stimulants, peptides, diuretics, nicotine, recreational drugs, and other endocrine-active agents increasingly appear alongside traditional anabolic steroid use. That means many patients are not presenting with a pure anabolic steroid syndrome. They are presenting with a blended pharmacologic state shaped by multiple interacting mechanisms. [1,2]

This changes how the clinician should think about attribution. A patient may be hypertensive from several converging pathways, psychiatrically unstable because stimulants and androgens are interacting, infertile because of prolonged suppression, and metabolically volatile because multiple hormones and IPEDs are layered together. If the clinician insists on finding one culprit, the case will feel disorganized. Once polypharmacy is treated as a default possibility rather than an exception, the syndrome becomes much easier to understand, prioritize, and manage. The practical shift is from single-agent explanation to exposure-state interpretation.

➅ Red Flags for Clinicians

Certain findings should immediately prompt direct, nonjudgmental inquiry into AAS or iPED exposure. Elevated hematocrit in an otherwise healthy-appearing patient, very low HDL, severe or resistant hypertension, unexplained liver enzyme elevation, significant acne or rapid-onset androgenic alopecia, erectile dysfunction or libido loss out of proportion to age, fertility impairment, and rapid extreme body-composition change all deserve specific exposure questioning. Psychiatric changes, especially post-cycle depression or panic, should be treated the same way. [1,11-13,20,21]

The red flag is not just the abnormality itself. It is the mismatch between the patient’s apparent health, stated history, and the degree of physiologic disruption being seen. Those mismatches are often where the diagnosis begins.

➆ Dependency & Use Disorder Patterns

Dependency patterns are common enough that clinicians should actively look for them. These may include compulsive continuation despite harm, psychological dependence on physique or performance, repeated cycling with inability to discontinue, and withdrawal states marked by fatigue, depression, sexual dysfunction, and loss of identity. [1-3,7-10,22]

Withdrawal is one of the most important barriers to change. Some patients resume use not because they are seeking enhancement in the abstract, but because the post-cycle state feels intolerable. If the clinician underestimates the physiologic and psychological severity of that period, nonadherence will be misread as lack of motivation rather than as a predictable consequence of exposure and recovery physiology. That mistake can make the clinician sound moralizing when the patient is actually describing a real and destabilizing withdrawal process.

➇ The Disclosure Barrier

Fear of stigma, fear of professional or social consequences, prior negative healthcare experiences, and lack of confidence in clinician knowledge all contribute to delayed disclosure of IPED use. Literature has shown that many men using AAS distrust clinicians and believe they are unlikely to receive useful or informed guidance in traditional medical settings. [1,2,9,10]

A confrontational approach often reduces disclosure. Explicit clarification of the clinician’s role also helps. In many cases, the first meaningful success in the encounter is not cessation. It is obtaining a more accurate history than the patient has given anyone before, because without that history the entire clinical picture remains partially hidden.

➈ Ethical & Clinical Positioning

Patients using AAS and iPEDs deserve the same standard of evidence-based, ethical medical care as any other population, even when the exposure itself is nonmedical. Harm reduction in this setting is disciplined medicine applied to a patient who may not yet be ready for cessation but is already experiencing real and often cumulative risk. [1,2]

The clinician’s role is to identify risk, reduce preventable harm, build enough trust to keep the patient engaged, and move care from secrecy toward structure. That balance is what makes the approach both ethically serious and clinically useful.

➉ Closing Framework

The clinical presentation of AAS and iPED use is not rare, and it is not somebody else’s problem. These patients are already moving through primary care, psychiatry, cardiology, fertility clinics, urgent care, and hormone practices, often carrying serious risk long before the exposure history is clearly stated. The clinician who recognizes the pattern early changes the entire trajectory of the case.

That is the real closing lesson of this course. Good clinicians do not wait for a perfect confession before they begin thinking clearly. They recognize when the physiology, the symptoms, the laboratory abnormalities, and the behavior no longer fit an ordinary endocrine presentation. Once that happens, the task is to ask directly, reduce avoidable harm, and move the patient from secrecy and fragmentation toward medically structured care. [1-10]

REFERENCES

Bonnecaze AK, O’Connor T, Burns CA. Harm reduction in male patients actively using anabolic androgenic steroids (AAS) and performance-enhancing drugs (PEDs): a review. J Gen Intern Med. 2021;36(7):2055-2064. doi:10.1007/s11606-021-06751-3
Anawalt BD. Diagnosis and management of anabolic androgenic steroid use. J Clin Endocrinol Metab. 2019.
Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341-375.
Goldman AL, Pope HG Jr, Bhasin S. The health threat posed by the hidden epidemic of anabolic steroid use and body image disorders among young men. J Clin Endocrinol Metab. 2019;104(4):1069-1074.
Kanayama G, Pope HG Jr. History and epidemiology of anabolic androgens in athletes and non-athletes. Mol Cell Endocrinol. 2018;464:4-13.
Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271-1279.
Pope HG Jr, Khalsa JH, Bhasin S. Body image disorders and abuse of anabolic-androgenic steroids among men. JAMA. 2017;317(1):23-24.
Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG Jr. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. 2009;104(12):1966-1978.
Pope HG Jr, Kanayama G, Ionescu-Pioggia M, Hudson JI. Anabolic steroid users’ attitudes towards clinicians. Addiction. 2004;99(9):1189-1194.
Harvey O, Keen S, Parrish M, van Teijlingen E. Support for people who use anabolic androgenic steroids: a systematic scoping review into what they want and what they access. BMC Public Health. 2019;19(1):1024.
Achar S, Rostamian A, Narayan SM. Cardiac and metabolic effects of anabolic-androgenic steroid abuse. Am J Cardiol. 2010;106(6):893-901.
Baggish AL, Weiner RB, Kanayama G, et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21):1991-2002.
Chang S, Münster AMB, Gram J, Sidelmann JJ. Anabolic androgenic steroid abuse: the effects on thrombosis risk, coagulation, and fibrinolysis. Semin Thromb Hemost. 2018;44(8):734-746.
de Souza GL, Hallak J. Anabolic steroids and male infertility: a comprehensive review. BJU Int. 2011;108(11):1860-1865.
Coward RM, Rajanahally S, Kovac JR, Smith RP, Pastuszak AW, Lipshultz LI. Anabolic steroid induced hypogonadism in young men. J Urol. 2013;190(6):2200-2205.
Herlitz LC, Markowitz GS, Farris AB, et al. Development of focal segmental glomerulosclerosis after anabolic steroid abuse. J Am Soc Nephrol. 2010;21(1):163-172.
Almukhtar SE, Abbas AA, Muhealdeen DN, Hughson MD. Acute kidney injury associated with androgenic steroids and nutritional supplements in bodybuilders. Clin Kidney J. 2015;8(4):415-419.
Bond P, Llewellyn W, Van Mol P. Anabolic androgenic steroid-induced hepatotoxicity. Med Hypotheses. 2016;93:150-153.
Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93(3):914-919.
Hauger LE, Westlye LT, Bjørnebekk A. Anabolic androgenic steroid dependence is associated with executive dysfunction. Drug Alcohol Depend. 2020;208:107874.
Thiblin I, Runeson B, Rajs J. Anabolic androgenic steroids and suicide. Ann Clin Psychiatry. 1999;11(4):223-231.
Smit DL, de Ronde W. Outpatient clinic for users of anabolic androgenic steroids: an overview. Neth J Med. 2018;76(4):167-175.

Clinical Presentation of Anabolic Androgenic Steroid Use & IPED Use Disorders